<scp>Guillain‐Barré</scp> Syndrome in a Patient With Minimal Symptoms of <scp>COVID</scp>‐19 Infection

Oguz‐Akarsu, Emel; Özpar, Rıfat; Mirzayev, Haci; Acet‐Ozturk, Nilufer Aylin; Hakyemez, Bahattin; Ediger, Dane; Karlı, Necdet

doi:10.1002/mus.26992

Cited by 51 publications

(70 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Referente al tratamiento, en la mayoría de los pacientes (90%) se utilizaron las inmunoglobulinas y en algunos estudios se añadió la terapia retroviral (27%) e hidroxicloroquina (40%), con la excepción de los estudios de Juliao et al, donde no se utilizan inmunoglobulinas, sino que solamente hidroxicloroquina, prednisona y terapia retroviral 15 , el de Marta-Enguita et al, donde se prescribe morfina, AINE, pirazolonas, amoxicilina, azitromicina y ácido clavulánico, por último encontramos el estudio de Oguz-Akarsu et al, quien utiliza transfusiones de plasma sanguíneo, hidroxicloroquina y azitromicina 16 , 17 .…”

Section: Resultsunclassified

Relación entre COVID-19 y síndrome de Guillain-Barré en adultos. Revisión sistemática

Gittermann¹,

Feris²,

Giacoman³

2020

Neurología

View full text Add to dashboard Cite

Introducción Se han reportado distintos casos de pacientes con cuadro de síndrome de Guillain-Barré asociado a COVID-19, pero falta mucha información aún sobre esta asociación y sus implicancias, el objetivo de esta revisión es analizar la evidencia disponible en esta temática en la población adulta. Material y Métodos Se realizó una revisión sistemática de estudios publicados en buscadores científicos: PubMed, Cochrane, Science Direct, Medline, OMS COVID-19. Resultados Se identificaron 45 estudios, los cuales se analizaron y completaron utilizando la plataforma Covidence, incluyendo para el análisis final 24 artículos y sumando un total de 30 pacientes. Conclusiones Se demuestra una asociación fuerte entre ambas patologías, además, los estudios analizados recalcan diferencias en la presentación de la enfermedad con mayor gravedad en los cuadros de síndrome de Guillain-Barré asociados a COVID-19.

show abstract

Section: Resultsunclassified

Relación entre COVID-19 y síndrome de Guillain-Barré en adultos. Revisión sistemática

Gittermann¹,

Feris²,

Giacoman³

2020

Neurología

View full text Add to dashboard Cite

show abstract

“… EMG/NCS: conduction blocks and temporal dispersion in right median/ulnar/peroneal CMAPs, normal right median/ulnar/peroneal F waves with decreased persistence, normal right sural/median/ulnar SNAPs, overall suggestive of demyelination. Plasma exchange (5 sessions every other day), hydroxychloroquine Favorable, recovery within 2 weeks ( Oguz-Akarsu et al, 2020 ) Acute Motor and Sensory Axonal Neuropathy (AMSAN) Northern Italy 77, F Same-day rapidly progressive tetraplegia, facial weakness, areflexia, upper limb paresthesia (36 h later), & respiratory failure (day 6) Fever, cough & ageusia (7 days prior) Lymphocytopenia, ↑ CRP & LDH, ketonuria; negative anti-GM1, GQ1b & GD1b antibodies; positive COVID-19 nasopharyngeal swab. Day 2: normal.…”

Section: Neurologic Manifestationsmentioning

confidence: 99%

SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation

Keyhanian

Umeton

Mohit

et al. 2021

Journal of Neuroimmunology

117

146

View full text Add to dashboard Cite

Since the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a growing body of evidence indicates that besides common COVID-19 symptoms, patients may develop various neurological manifestations affecting both the central and peripheral nervous systems as well as skeletal muscles. These manifestations can occur prior, during and even after the onset of COVID-19 general symptoms. In this Review, we discuss the possible neuroimmunological mechanisms underlying the nervous system and skeletal muscle involvement, and viral triggered neuroimmunological conditions associated with SARS-CoV-2, as well as therapeutic approaches that have been considered for these specific complications worldwide.

show abstract

“…Finally, several authors reported cases of Guillain-Barré syndrome associated with SARS-CoV-2 infection [39][40][41][42]. The main etiopathological hypothesis involves "molecular mimicry", by which specific viral antigens and myelin or axonal epitopes may lead to cross-reactive of immune responses and inflammatory damage of the peripheral nerve fibres.…”

Section: Neurological Symptoms Associated With Sars-cov-2mentioning

confidence: 99%

Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients

et al. 2020

View full text Add to dashboard Cite

COVID-19 is a pandemic caused by human coronavirus (HCoV) SARS-CoV-2, which originated in Wuhan, China, at the end of 2019 and spread globally during 2020. Due to the difficulty of clinical decision-making during this period, our study group reviewed current literature focusing on the neurological and psychiatric aspects of COVID-19. Despite the knowledge on this newly discovered virus which is constantly evolving, different pieces of evidence reported an association between COVID-19 and neurological symptoms like headache, dizziness, taste and smell disorders and complications involving the nervous system eventually triggered by the pathologic processes elicited by SARS-CoV-2. It seems that younger patients are less prone to develop severe forms of COVID-19. However, neurological signs have been reported in paediatric patients as well, and in some cases, the infection presented neurological sequelae. Furthermore, children with particular neurological diseases or treated with specific drugs (e.g. immune-suppressant therapies) must be carefully monitored during this pandemic. Neurologists should be aware of the main drug-drug interactions and the neurological side effects of COVID-19 treatments. Notably, adverse mental health impact has been reported in patients with SARS-CoV-2, which could be related either to the social strain or to the eventual neurotropic effects of the virus, which in other infections have been proven to promote the onset of psychiatric symptoms. Further, psychiatric population may be more vulnerable to the infection and at higher risk for adverse outcomes.

show abstract

Guillain‐Barré Syndrome in a Patient With Minimal Symptoms of COVID‐19 Infection

Cited by 51 publications

References 7 publications

Relación entre COVID-19 y síndrome de Guillain-Barré en adultos. Revisión sistemática

Relación entre COVID-19 y síndrome de Guillain-Barré en adultos. Revisión sistemática

SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation

Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients

Contact Info

Product

Resources

About